Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Galland, L.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Minocycline and Rheumatoid Arthritis Revisited

right arrow Leo Galland, MD

1 September 1995 | Volume 123 Issue 5 | Pages 392-393


TO THE EDITOR:

In his editorial on minocycline treatment of rheumatoid arthritis, Dr. Paulus compares the favorable outcome to the outcome seen with treatment of a smoldering chronic infection [1]. The partial remission induced by minocycline therapy and relapse following its discontinuation suggest that antibiotic responsiveness may actually address a secondary "infection" induced by nonsteroidal anti-inflammatory drugs (NSAIDs) taken by all patients throughout the Monocycline in Rheumatoid Arthritis (MIRA) clinical trial [2]. Long-term NSAID exposure produces intestinal hyperpermeability and inflammation, which cannot be reversed by misoprostol but which is both prevented and reversed by the administration of metronidazole [3]. Therapy with NSAIDs to treat rheumatoid arthritis increases patients' antibody levels to Clostridium perfringens and its {alpha} toxin [4]. Bacterial cell-wall polymers isolated from normal enteric anaerobes can induce chronic arthritis in experimental animals [5]. Therapy with NSAIDs increases intestinal permeability and allows sensitization to components of the indigenous flora of the gut; these actions may not only cause an inflammatory enteritis, reversible by antibiotic agents but may aggravate inflammatory arthritis, a condition also reversible by antibiotic agents. This theory can be readily tested by comparing changes in intestinal lactulose permeability and stool leukocyte counts with changes in clinical variables.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

New York, NY 10021


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Paulus HE. Minocycline treatment of rheumatoid arthritis [Editorial]. Ann Intern Med. 1995; 122:147-8.

2. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 122:81-9.

3. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci. 1993; 38:417-25.

4. Dearlove M, Barr K, Neuman V, Bird HA, Gool HC, Wright V. The effect of non-steroidal anti-inflammatory drugs of faecal flora nd bacterial antibody levels in rheumatoid arthritis. Br J Rheumatol. 1992; 31:443-7.

5. Severijnen AJ, Kool J, Swack AJ, Hazenberg MP. Intestinal flora of patients with rheumatoid arthritis: induction of chronic arthritis in rats by cell wall fragments of Eubacterium aerofaciens strain. Br J Rheumatol. 1990; 29:433-9.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Galland, L.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online